Table 2:
Best overall response based on investigator assessment by modified RECIST 1.1
| Durva/treme (n=26) |
Durva/treme Low-dose radiation (n=26) |
Durva/treme Hypofractionated radiation (n=26) |
Total population (n=78) |
|
|---|---|---|---|---|
| Best overall response | ||||
| Partial response | 3 (11.5, 1.2-21.8) | 2 (7.7, 0-16.3) | 3 (11.5, 1.2-21.8) | 8 (10.3, 5-18) |
| Stable disease | 11 (42.3) | 12 (46.2) | 10 (38.5) | 33 (42.3) |
| Progressive disease | 10 (38.5) | 8 (30.8) | 10 (38.5) | 28 (35.9) |
| Not Evaluable | 2 (7.7) | 4 (15.4) | 2 (7.7) | 8 (10.3) |
| Pairwise comparison with no radiation arm | ||||
| Difference in response rate | NA | −3.8% (90% CI: −17.3%-9.6%) | 0% (−14.6%, 14.6%) | NA |
| Chi-squared p-value | NA | 0.64 | 0.99 | NA |
| Disease control | 8 (30.8, 15.9-45.7) | 6 (23.1, 9.5-36.7) | 9 (34.6, 19.3-50.0) | 23 (29.5, 21-39) |
| Pairwise comparison with no radiation arm | ] | |||
| Difference in response rate | NA | −7.7% (90% CI: −27.9%-12.5%) | 3.8% (90% CI: −17.5%-25.2%) | NA |
| Chi-squared p-value | NA | 0.53 | 0.77 | NA |
Data are n (%, 90% confidence interval) according to RECIST 1.1=Response Evaluation Criteria in Solid Tumors version 1.1 excluding responses in irradiated lesions. Note: No complete responses were observed.